Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger
Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.
